AskBio宣布在欧洲基因与细胞治疗学会第32届年会上发表6场演讲-动脉网

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting

拜耳等信源发布 2025-10-02 20:02



可切换为仅中文







October

十月

2025

14:00 PM

Europe/Amsterdam

欧洲/阿姆斯特丹

AskBio Announces 6 Presentations at the European Society of Gene and Cell Therapy 32nd Annual Meeting

AskBio 宣布在欧洲基因与细胞治疗学会第32届年会上进行6场报告

Summary

摘要

One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in the company’s manufacturing technologies

一次口头报告和五次海报展示将突出AskBio公司在研发管线中的令人兴奋的进展以及公司在制造技术方面的进步。

Research Triangle Park, N.C.– OCTOBER 2, 2025

北卡罗来纳州研究三角园区 – 2025年10月2日

–

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver

AskBio Inc. （AskBio），一家由拜耳公司全资拥有并独立运营的基因治疗公司，将交付成果。

presentations offering insights into the research and development of adeno-associated virus (AAV) therapies for a range of diseases as well as advancements in manufacturing technologies, at the European Society of Gene and Cell Therapy (ESGCT) 32

在欧洲基因与细胞治疗学会 (ESGCT) 第32届会议上，展示关于一系列疾病腺相关病毒 (AAV) 疗法的研发以及制造技术进步的见解。

Annual Meeting taking place October 7–10, 2025, in Seville, Spain.

年度会议将于2025年10月7日至10日在西班牙塞维利亚举行。

“ESGCT brings together leading researchers, clinicians, and industry experts to drive forward the field of gene and cell therapy and, as a company with a significant presence both in U.S. and Europe, this meeting is a special opportunity for us to interact with these prestigious stakeholders,” said Gustavo Pesquin, Chief Executive Officer, AskBio.

“ESGCT汇集了基因和细胞治疗领域的顶尖研究人员、临床医生和行业专家，作为一家在美欧均有重要影响力的公司，此次会议为我们提供了一个与这些杰出的利益相关者互动的特殊机会，”AskBio首席执行官古斯塔沃·佩斯金表示。

“This year, alongside Viralgen, AskBio is contributing six presentations that highlight not only our latest clinical milestones but also our advanced manufacturing capabilities. As we share new data spanning discovery, preclinical, and clinical stages, we reaffirm our commitment to delivering therapies at scale, with robust production and translational excellence.

“今年，与Viralgen一起，AskBio将贡献六场演讲，不仅展示我们最新的临床里程碑，还展示我们先进的制造能力。在分享涵盖发现、临床前和临床阶段的新数据时，我们重申了以强大的生产和转化卓越性大规模交付治疗方案的承诺。”

It is through this confluence of scientific rigor and operational strength that we aim to translate hope into real-world impact for patients facing serious and rare diseases.'.

正是通过这种科学严谨性和运营实力的结合，我们旨在将希望转化为对面临严重和罕见疾病的患者产生现实影响。

AskBio’s presentations include (all times CEST):

AskBio的演讲包括（所有时间均为欧洲中部夏令时间）：

Oral

口腔的

Delivery technologies: A Strategic Platform Roadmap for Commercializing Gene Therapy. Wed., Oct. 8, from 18:00-19:30 (Session 6ª: Manufacturing 1: Delivery technologies, Parallel A). Cesar Trigueros, PhD, Chief Scientific Officer, Viralgen.

交付技术：基因治疗商业化的战略平台路线图。10月8日星期三18:00-19:30（第六场A：制造1：交付技术，平行A）。塞萨尔·特里格罗斯博士，Viralgen首席科学官。

Posters

海报

Optimized Adenovirus Helper Plasmids for Enhanced Production of Recombinant AAV Vectors with Improved Quality (Poster #P0215). Wed., Oct. 8, from 14:00-15:30. Achille Francois, Viralgen.

优化的腺病毒辅助质粒用于提高重组AAV载体的生产及质量（海报#P0215）。10月8日星期三，14:00-15:30。阿希尔·弗朗索瓦，Viralgen公司。

Development of Antibody-escaping AAV Vectors Through Modular Assembly and Selection with IVIG (Poster #P0223). Wed., Oct. 8, from 14:00-15:30. Carlos Martin de Hijas, AskBio.

通过模块化组装和IVIG筛选开发逃逸抗体的AAV载体（海报#P0223）。10月8日星期三，14:00-15:30。卡洛斯·马丁·德·希哈斯，AskBio。

A Platform Approach for Streamlining and Accelerating Gene Therapy Commercialization (Poster #P0249). Wed., Oct. 8, from 14:00-15:30. Silvia Gomez, Viralgen.

一种简化和加速基因治疗商业化的平台方法（海报#P0249）。10月8日星期三，14:00-15:30。Silvia Gomez，Viralgen。

Control of Gene Expression for Precision Treatment of Genetic Diseases (Poster #P0086). Thu., Oct. 9, from 14:00 to 15:00. Graham Whyteside, AskBio.

精准治疗遗传病的基因表达控制（海报#P0086）。10月9日星期四，14:00至15:00。Graham Whyteside，AskBio。

Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing (Poster #P0138). Thu., Oct. 9, from 14:00 to 15:00. Itsasne Arangoa, Viralgen.

整合拉曼光谱与基因组规模建模以提升AAV上游生产（海报#P0138）。10月9日星期四，14:00至15:00。Itsasne Arangoa，Viralgen。

With an ambitious portfolio of gene therapies at various stages of research and development, AskBio continues to develop AAV-based therapies to treat some of the world’s most debilitating diseases, including Congestive Heart Failure, Limb-Girdle Muscular Dystrophy, Multiple System Atrophy, Parkinson’s disease, and Pompe disease.

AskBio拥有一个处于不同研发阶段的基因疗法的宏大产品组合，继续开发基于AAV的疗法，以治疗一些世界上最使人衰弱的疾病，包括充血性心力衰竭、肢带型肌营养不良、多系统萎缩症、帕金森病和庞贝病。

By targeting diseases in several therapeutic areas, AskBio aims to deliver breakthrough treatments that could benefit more than 35 million patients worldwide..

通过针对多个治疗领域的疾病，AskBio 旨在提供突破性治疗方法，有望惠及全球超过 3500 万名患者。

1–7

About AskBio

关于AskBio

AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications with a clinical-stage pipeline that includes investigational therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson’s disease, and Pompe disease.

AskBio Inc. 是拜耳集团全资拥有并独立运营的子公司，是一家完全集成的基因治疗公司，致力于开发挽救生命的药物并改变生命。该公司在神经肌肉、中枢神经系统、心血管和代谢疾病适应症范围内拥有多项临床计划，其临床阶段的产品线包括用于治疗充血性心力衰竭、肢带型肌营养不良、多系统萎缩、帕金森病和庞贝病的在研治疗药物。

AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive array of capsids and promoters. With global headquarters in Research Triangle Park, North Carolina, United States, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing.

AskBio的基因治疗平台包括Pro10™，一种行业领先的专有细胞系制造工艺，以及一系列广泛的衣壳和启动子。公司总部位于美国北卡罗来纳州三角研究园，已经开发了数百种专有的衣壳和启动子，其中几种已进入临床前和临床测试阶段。

An early innovator in the gene therapy field, with over 900 employees in five countries, the company holds more than 600 patents and patent applications in areas such as adeno-associated virus (AAV) production and chimeric capsids. Learn more at .

作为基因治疗领域的早期创新者，该公司在五个国家拥有超过900名员工，并在腺相关病毒（AAV）生产和嵌合衣壳等领域拥有600多项专利和专利申请。欲了解更多信息，请访问。

www.askbio.com

or follow us on

或关注我们

领英

。

About Viralgen Vector Core

关于Viralgen载体核心

Viralgen, founded in 2017 as a subsidiary of AskBio Inc. within the Bayer AG group, is a Contract Development and Manufacturing Organization (CDMO) specialized in the large-scale production of cGMP adeno-associated virus (AAV) for gene therapies. Utilizing the Pro10™ proprietary suspension manufacturing platform, Viralgen achieves high AAV titers, enhancing clinical development and commercialization efficiency.

Viralgen成立于2017年，是拜耳集团旗下的AskBio Inc.的子公司，是一家专注于基因治疗用cGMP腺相关病毒（AAV）大规模生产的合同开发和制造组织（CDMO）。通过使用Pro10™专有悬浮制造平台，Viralgen实现了高AAV滴度，提升了临床开发和商业化效率。

Located in San Sebastian, Spain, its state-of-the-art facility features seven cGMP suites, three with over 2,000L capacities, all certified by AEMPS (the Spanish Agency for Medicines and Medical Devices). The company also offers advanced services for transitioning from clinical to commercial manufacturing and has recently expanded its development services to include construct and process optimization.

位于西班牙圣塞巴斯蒂安，其最先进的设施包括七个cGMP套件，其中三个容量超过2,000升，所有套件均通过西班牙药品和医疗器械管理局（AEMPS）认证。该公司还提供从临床过渡到商业生产的先进服务，并最近扩展了其开发服务，涵盖构建和工艺优化。

For more information, visit .

如需更多信息，请访问。

https://viralgen.com

。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无人饥饿”的使命，公司通过支持应对不断增长和老龄化的全球人口所带来的重大挑战，设计其产品和服务以帮助人类和地球繁荣发展。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表着信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用共计62亿欧元。欲了解更多信息，请访问。

http://www.bayer.com

。

AskBio Forward-Looking Statements

AskBio 前瞻性声明

This press release contains “forward-looking statements.” Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements.

本新闻稿包含“前瞻性陈述”。本新闻稿中包含的任何非历史事实的陈述可能被视为前瞻性陈述。诸如“相信”、“预期”、“计划”、“预计”、“将”、“意图”、“潜力”、“可能”等词语及类似表述旨在识别前瞻性陈述。

These forward-looking statements include, without limitation, statements regarding AskBio’s clinical trials. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio’s control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned clinical and regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office.

这些前瞻性陈述包括但不限于有关AskBio临床试验的声明。这些前瞻性陈述涉及许多风险和不确定性，其中许多是AskBio无法控制的。已知的风险包括，但不限于：由于各种原因，AskBio可能无法执行其商业计划和目标，包括无法达成预期或计划中的临床和监管里程碑及时间表、对第三方的依赖、临床开发计划、制造流程与计划，以及将其产品候选药物推向市场，这些原因包括公司财务及其他资源的可能限制、可能未能及时预见或解决的制造限制、与第三方合作者和合作伙伴之间可能出现的分歧或其他问题，以及来自监管机构、法院或相关机构的反馈或决定，例如来自美国食品药品监督管理局或美国专利商标局的反馈和决定。

Any of the foregoing risks could materially and adversely affect AskBio’s business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof..

上述任何风险都可能对AskBio的业务和经营结果产生重大不利影响。您不应过度依赖本新闻稿中包含的前瞻性声明。AskBio不承担基于此后发生的事件或情况公开更新其前瞻性声明的义务。

Media Contact:

媒体联系人:

Phil McNamara

菲尔·麦克纳马拉

Vice President, Corporate Communications, AskBio

AskBio公司传播副总裁

错误：

pmcnamara@askbio.com

T +1 984.520.7211

电话：+1 984.520.7211

Downloads